{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:18:53Z","timestamp":1794590333330,"version":"4.9.1"},"reference-count":50,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2022,11,1]]},"abstract":"<jats:sec id=\"ab-eoi220060-4\"><jats:title>Importance<\/jats:title><jats:p>Diverse enrollment and adequate representation of racial and ethnic minority groups in randomized clinical trials (RCTs) are valuable to ensure external validity and applicability of results.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi220060-5\"><jats:title>Objective<\/jats:title><jats:p>To compare the distribution of race and ethnicity in RCTs of diabetic macular edema (DME) and macular edema from retinal vein occlusion (RVO) to that of US Census data.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi220060-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This was a cross-sectional retrospective analysis comparing racial and ethnic demographic characteristics of US-based RCTs of DME and RVO between 2004 and 2020 with 2010 US Census data. PubMed and ClinicalTrials.gov were searched to screen for completed phase 3 RCTs with published results. Of 169 trials screened, 146 were excluded because they were incomplete, did not report race and ethnicity, or were not based in the US, and 23 trials were included (15 DME and 8 RVO). The number and percentage of American Indian or Alaska Native, Asian, Black, Hispanic, Native Hawaiian or Other Pacific Islander, and White participants was recorded in each RCT. The demographic distribution and proportion was compared to the reported distribution and proportion in the 2010 US Census using the \u03c7<jats:sup>2<\/jats:sup> test.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi220060-7\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Overrepresentation, underrepresentation, or representation commensurate with 2010 US Census data in the racial and ethnic populations of RCTs of retinal vascular disease.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi220060-8\"><jats:title>Results<\/jats:title><jats:p>In 23 included RCTs of DME and RVO, there were a total of 38 participants (0.4%) who identified as American Indian or Alaska Native and Native Hawaiian or Other Pacific Islander (groups combined owing to small numbers), 415 Asian participants (4.4%), 904 Black participants (9.6%), 954 Hispanic participants (10.1%), and 7613 White participants (80.4%). By comparison, the 2010 US Census data indicated that 1.1% of the US population self-reported as American Indian or Alaska Native and Native Hawaiian or Other Pacific Islander (groups combined for comparison in this study), 4.8% self-reported as Asian, 12.6% as Black or African American, 16.3% as Hispanic, and 63.7% as White. American Indian or Alaska Native and Hawaiian or Other Pacific Islander participants were underrepresented in 2 trials, neither overrepresented nor underrepresented in 20, and not overrepresented in any of the included trials. Asian participants were underrepresented in 10 trials, overrepresented in 4, and neither overrepresented nor underrepresented in 8. Black participants were underrepresented in 9 trials, overrepresented in 2, and neither overrepresented nor underrepresented in 11. Hispanic participants were underrepresented in 15 trials, overrepresented in 2, and neither overrepresented nor underrepresented in 5. White participants were underrepresented in 2 trials, overrepresented in 14, and neither overrepresented nor underrepresented in 7. The \u03c7<jats:sup>2<\/jats:sup> values comparing RCT demographic distribution to US 2010 Census data were significantly different in 22 of 23 included RCTs.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi220060-9\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>The findings in this study indicated a discrepancy between racial and ethnic demographic data in RCTs of DME and RVO and the US population according to the 2010 Census. White study participants were most frequently overrepresented, and Hispanic study participants were most frequently underrepresented. These findings support the need for more efforts to recruit underrepresented racial and ethnic minorities to improve external validity in trial findings.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2022.3929","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T15:41:03Z","timestamp":1665070863000},"page":"1096","source":"Crossref","is-referenced-by-count":37,"title":["Representation of Race and Ethnicity in Randomized Clinical Trials of Diabetic Macular Edema and Retinal Vein Occlusion Compared to 2010 US Census Data"],"prefix":"10.1001","volume":"140","author":[{"given":"Abdul-Hadi","family":"Kaakour","sequence":"first","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Uyen","family":"Hua","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Rachitskaya","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"eoi220060r2","first-page":"7","article-title":"Care of culturally diverse patients undergoing ophthalmic surgery.","volume":"36","author":"Wright","year":"2011","journal-title":"Insight"},{"issue":"8","key":"eoi220060r3","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.ophtha.2004.01.025","article-title":"Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study.","volume":"111","author":"Varma","year":"2004","journal-title":"Ophthalmology"},{"issue":"5","key":"eoi220060r4","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.ajo.2009.11.014","article-title":"Four-year incidence and progression of diabetic retinopathy and macular edema: the Los Angeles Latino Eye Study.","volume":"149","author":"Varma","year":"2010","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"eoi220060r5","doi-asserted-by":"publisher","DOI":"10.2196\/16377","article-title":"Big data in context: addressing the twin perils of data absenteeism and chauvinism in the context of health disparities research.","volume":"22","author":"Lee","year":"2020","journal-title":"J Med internet Res"},{"issue":"10","key":"eoi220060r9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1870","article-title":"Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018.","volume":"5","author":"Loree","year":"2019","journal-title":"JAMA Oncol"},{"issue":"6","key":"eoi220060r13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1001\/jamaophthalmol.2021.0857","article-title":"Racial\/ethnic disparities in ophthalmology clinical trials resulting in US Food and Drug Administration Drug approvals from 2000 to 2020.","volume":"139","author":"Berkowitz","year":"2021","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"eoi220060r14","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jnma.2017.12.004","article-title":"Gender and ethnicity of enrolled participants in U.S. Food and Drug Administration (FDA) clinical trials for approved ophthalmological new molecular entities.","volume":"110","author":"Birnbaum","year":"2018","journal-title":"J Natl Med Assoc"},{"key":"eoi220060r15","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.12688\/f1000research","article-title":"Randomized controlled trials in ophthalmology: a bibliometric study.","volume":"8","author":"AlRyalat","year":"2019","journal-title":"F1000Res"},{"issue":"11","key":"eoi220060r16","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/jamaophthalmol.2014.2854","article-title":"Prevalence of and risk factors for diabetic macular edema in the United States.","volume":"132","author":"Varma","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"eoi220060r19","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1001\/archopht.122.4.552","article-title":"The prevalence of diabetic retinopathy among adults in the United States.","volume":"122","author":"Kempen","year":"2004","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"eoi220060r21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","article-title":"The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia.","volume":"117","author":"Rogers","year":"2010","journal-title":"Ophthalmology"},{"issue":"10","key":"eoi220060r22","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1167\/iovs.08-1826","article-title":"Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multiethnic study of atherosclerosis.","volume":"49","author":"Cheung","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"eoi220060r23","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/archophthalmol.2009.234","article-title":"A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5.","volume":"127","author":"Ip","year":"2009","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"eoi220060r24","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.ophtha.2008.06.015","article-title":"A randomized trial comparing intravitreal triamcinolone acetonide and focal\/grid photocoagulation for diabetic macular edema.","volume":"115","author":"Diabetic Retinopathy Clinical Research Network","year":"2008","journal-title":"Ophthalmology"},{"issue":"11","key":"eoi220060r25","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.2337\/dc10-0493","article-title":"Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study.","volume":"33","author":"Massin","year":"2010","journal-title":"Diabetes Care"},{"issue":"8","key":"eoi220060r26","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1016\/j.ophtha.2012.02.010","article-title":"One-year outcomes of the da Vinci study of VEGF trap-eye in eyes with diabetic macular edema.","volume":"119","author":"Do","year":"2012","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi220060r27","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1097\/IAE.0b013e318217d739","article-title":"Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal\/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation.","volume":"31","author":"Googe","year":"2011","journal-title":"Retina"},{"issue":"6","key":"eoi220060r28","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.ophtha.2011.02.045","article-title":"A phase 2\/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema.","volume":"118","author":"Sultan","year":"2011","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi220060r29","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"issue":"12","key":"eoi220060r30","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1038\/eye.2015.142","article-title":"Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the Macula in Diabetes-Protocol 3 With High Dose).","volume":"29","author":"Do","year":"2015","journal-title":"Eye (Lond)"},{"issue":"6","key":"eoi220060r31","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1136\/bjophthalmol-2015-307249","article-title":"Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study.","volume":"100","author":"Pr\u00fcnte","year":"2016","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"eoi220060r32","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","article-title":"Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.","volume":"117","author":"Elman","year":"2010","journal-title":"Ophthalmology"},{"issue":"11","key":"eoi220060r33","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","article-title":"Intravitreal aflibercept for diabetic macular edema.","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"issue":"13","key":"eoi220060r34","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.","volume":"372","author":"Wells","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"eoi220060r35","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1001\/jama.2019.5790","article-title":"Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial.","volume":"321","author":"Baker","year":"2019","journal-title":"JAMA"},{"issue":"23","key":"eoi220060r36","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1001\/jama.2020.23027","article-title":"Effect of intravitreous aflibercept vs vitrectomy with panretinal photocoagulation on visual acuity in patients with vitreous hemorrhage from proliferative diabetic retinopathy: a randomized clinical trial.","volume":"324","author":"Antoszyk","year":"2020","journal-title":"JAMA"},{"issue":"6","key":"eoi220060r37","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","article-title":"Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.","volume":"117","author":"Haller","year":"2010","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi220060r38","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","article-title":"Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.","volume":"117","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi220060r39","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology"},{"issue":"12","key":"eoi220060r40","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1016\/j.ophtha.2014.06.011","article-title":"Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study.","volume":"121","author":"Campochiaro","year":"2014","journal-title":"Ophthalmology"},{"issue":"5","key":"eoi220060r41","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.ophtha.2012.01.042","article-title":"Vascular endothelial growth factor trap-eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study.","volume":"119","author":"Boyer","year":"2012","journal-title":"Ophthalmology"},{"issue":"3","key":"eoi220060r42","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1136\/bjophthalmol-2012-301504","article-title":"VEGF trap-eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study.","volume":"97","author":"Holz","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"20","key":"eoi220060r43","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1001\/jama.2017.4568","article-title":"Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion: the SCORE2 randomized clinical trial.","volume":"317","author":"Scott","year":"2017","journal-title":"JAMA"},{"issue":"6","key":"eoi220060r44","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.oret.2022.01.018","article-title":"Racial, ethnic, and gender disparities in diabetic macular edema clinical trials.","volume":"6","author":"Bowe","year":"2022","journal-title":"Ophthalmol Retina"},{"issue":"2","key":"eoi220060r45","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jnma.2021.12.016","article-title":"Race and ethnic representation among clinical trials for diabetic retinopathy and diabetic macular edema within the United States: a review.","volume":"114","author":"Sanjiv","year":"2022","journal-title":"J Natl Med Assoc"},{"issue":"8","key":"eoi220060r46","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1001\/jamaophthalmol.2020.2107","article-title":"Reporting of race and ethnicity in the ophthalmology literature in 2019.","volume":"138","author":"Moore","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"eoi220060r48","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ajo.2005.08.063","article-title":"Diabetic retinopathy in a multi-ethnic cohort in the United States.","volume":"141","author":"Wong","year":"2006","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"eoi220060r49","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.2337\/dc21-0228","article-title":"Incidence of proliferative diabetic retinopathy and other neovascular sequelae at 5 years following diagnosis of type 2 diabetes.","volume":"44","author":"Gange","year":"2021","journal-title":"Diabetes Care"},{"key":"eoi220060r50","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.ajo.2020.09.042","article-title":"The impact of race on short-term treatment response to bevacizumab in diabetic macular edema.","volume":"222","author":"Osathanugrah","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"eoi220060r7","volume-title":"Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care","author":"Institute of Medicine","year":"2003"},{"key":"eoi220060r1","unstructured":"Bureau? UC. The chance that two people chosen at random are of different race or ethnicity groups has increased since 2010.? US Census Bureau. Accessed January 1, 2022. https:\/\/www.census.gov\/library\/stories\/2021\/08\/2020-united-states-population-more-racially-ethnically-diverse-than-2010.html"},{"key":"eoi220060r6","unstructured":"Amendment: NIH policy and guidelines on the inclusion of women and minorities as subjects in clinical research\u2014October, 2001. Accessed January 1, 2022. https:\/\/grants.nih.gov\/grants\/guide\/notice-files\/NOT-OD-02-001.html"},{"key":"eoi220060r8","unstructured":"American College of Physicians. Racial and ethnic disparities in health care, update 2010. Published online 2010. Accessed September 7, 2022. https:\/\/www.acponline.org\/acp_policy\/policies\/racial_ethnic_disparities_2010.pdf"},{"key":"eoi220060r10","unstructured":"US Food and Drug Administration. Drug trials snapshots: summary report. Published online 2020. Accessed September 7, 2022. https:\/\/www.fda.gov\/media\/145718\/download"},{"key":"eoi220060r11","unstructured":"2015-2016 Global participation in clinical trials report. Published online July 2017. Accessed September 7, 2022. https:\/\/www.fda.gov\/media\/106725\/download"},{"key":"eoi220060r12","unstructured":"2015-2019 Drug Trials Snapshots Summary Report. Published online November 2020. https:\/\/www.fda.gov\/media\/143592\/download"},{"key":"eoi220060r17","unstructured":"US Department of Health and Human Resources Office of Minority Health. Profile: Black\/African Americans. Accessed January 1, 2022. https:\/\/www.minorityhealth.hhs.gov\/omh\/browse.aspx?lvl=3&lvlid=61"},{"key":"eoi220060r18","unstructured":"Office of Disease Prevention and Health Promotion. Disparities overview by race and ethnicity. Accessed January 1, 2022. https:\/\/www.healthypeople.gov\/2020\/data\/disparities\/summary\/Chart\/5380\/3"},{"key":"eoi220060r20","unstructured":"Ostchega? Y, Fryar? CD, Nwankwo? T, Nguyen? DT; US Centers for Disease Control and Prevention. Hypertension prevalence among adults aged 18 and over: United States, 2017-2018 (2020). NCHS data brief no. 364. Accessed September 7, 2022. https:\/\/www.cdc.gov\/nchs\/data\/databriefs\/db364-h.pdf"},{"key":"eoi220060r47","unstructured":"US Food and Drug Administration. Collection of race and ethnicity data in clinical trials: guidance for industry and Food and Drug Administration staff. Published online October 2016. Accessed September 7, 2022. https:\/\/www.fda.gov\/media\/75453\/download"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2797004\/jamaophthalmology_kaakour_2022_oi_220060_1668089434.09714.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T16:02:56Z","timestamp":1668700976000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2797004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.3929","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,1]]}}}